BioSpace News Archive

Various white pills and capsules forming a map of the world, illustrating humanity's increasing dependency on medication manufacturing.

Obesity

Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.

February 13, 2026

·

2 min read

·

Tristan Manalac

Earnings

All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts

Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.

February 13, 2026

·

2 min read

·

Tristan Manalac

Businessman on a crossroad. Man choosing career. Searching of right path. Decision and brainstorming concept. Flat vector illustration.

Earnings

Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation

Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.

February 13, 2026

·

5 min read

·

Annalee Armstrong

Adult people customers group in casual clothes standing in long line queue

Gene therapy

Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.

February 13, 2026

·

3 min read

·

Dan Samorodnitsky

Social media networking. Network with members connected with each other. Group of people. Communication, teamwork, community, society. Abstract concept with wooden pieces on blue background.

FDA

Moderna’s Outright Flu Refusal Just the Latest Case of Crossed FDA Signals

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.

February 13, 2026

·

6 min read

·

Heather McKenzie

Press Releases

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

February 13, 2026

·

9 min read

Press Releases

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025